Navigation Links
University of Cincinnati leads first trial on steroid and CNI withdrawal post-transplant
Date:11/28/2012

CINCINNATIThe University of Cincinnati will lead a $5.2 million national trial studying removal of both corticosteroids and common immunosuppression treatments from the post-transplant drug regimen for kidney transplant patients.

The Belatacept Early Steroid withdrawal Trial (BEST) seeks to determine if a belatacept-based regimen for post-transplant patients can prevent organ rejection without the harmful side effects posed by corticosteroids and calcineurin inhibitor (CNI) immunosuppressants. Belatacept is a modified version of the drug abatacept, which is used to treat rheumatoid arthritis.

Led by principal investigator and director of UC's division of transplantation E. Steve Woodle, MD, the $5.2 million trial will be carried out at four other transplant centers across the country: University of Wisconsin, University of Minnesota, California Pacific Medical Center and the Christ Hospital in Cincinnati.

The BEST study is the first large, multicenter trial to remove both corticosteroids and CNIs from a patient's drug regimen after kidney transplantation. Both drugs place patients at an increased risk of cardiovascular disease, high blood pressure, high cholesterol and diabetes. Additionally, CNIs have shown toxicity to transplanted kidneys.

"Cardiovascular events like stroke and heart attacks are the top cause of death for both the general population and transplant patients," says Woodle, who also serves as William A. Altemeier Chair in the UC Department of Surgery. "We've previously demonstrated that early steroid withdrawal results in reduced rates of rejection and increased graft survival in transplant patients."

Rita Alloway, PharmD, research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, will direct the coordinating center for the trial. She says belatacept was approved by the Food and Drug Administration in 2011 for prevention of rejection in kidney transplant patientsthe first FDA-approved drug to replace CNIs like tacrolimus and cyclosporine.

"This trial is a major step forward in immunosuppression because it provides a means to avoid many of the toxicities of the CNI drugs, particularly kidney toxicity, high blood pressure, and hyperlipidemia," says Alloway.

Adele Shields, PhD, associate research professor of surgery with clinical practice at the Christ Hospital, has specialized in quantitating the impact of long-term immunosuppression on cardiac risk factors and cardiac events.

"An important feature of the belatacept-based treatment regimen is that it provides an opportunity to greatly minimize cardiovascular risk in the long term," she says. "By avoiding both CNIs and corticosteroids, this trial provides an opportunity to substantially impact long-term patient survival following kidney transplantation."


'/>"/>

Contact: Kathryn Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University honoring Axel Ullrich with Lennox K. Black International Prize
2. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
3. University of Tennessee study: Unexpected microbes fighting harmful greenhouse gas
4. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
5. University of Pennsylvania Medicine receives National Institutes of Health grant to help local communities move forward after asbestos exposure
6. Allied Minds and The George Washington University partner to form LuxCath LLC
7. New era in metabolomics begins at University of Michigan
8. Umeå University hosts new World Health Organization Collaborating Centre
9. George Mason University researchers target breast cancer in 3 trials
10. Research prizes from the Carlsberg Foundation to researchers from University of Copenhagen
11. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology: